|
Kurmasheva, Raushan T; Kurmashev, Dias; Reynolds, C Patrick et al. (2018) Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 65:
|
|
Lock, Richard; Carol, Hernan; Maris, John M et al. (2017) Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. Pediatr Blood Cancer 64:
|
|
Kurmasheva, Raushan T; Sammons, Melissa; Favours, Edward et al. (2017) Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 64:
|
|
Kurmasheva, Raushan T; Gorlick, Richard; Kolb, E Anders et al. (2017) Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 64:
|
|
Attiyeh, Edward F; Maris, John M; Lock, Richard et al. (2016) Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. Pediatr Blood Cancer 63:276-86
|
|
Gorlick, Richard; Kolb, E Anders; Keir, Stephen T et al. (2016) Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 63:443-50
|
|
Kang, Min H; Reynolds, C Patrick; Kolb, E Anders et al. (2016) Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 63:1744-52
|
|
Smith, Malcolm A; Hampton, Oliver A; Reynolds, C Patrick et al. (2015) Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr Blood Cancer 62:91-8
|
|
Krishnamachari, Bhuma; Il'yasova, Dora; Scheurer, Michael E et al. (2015) A pooled multisite analysis of the effects of atopic medical conditions in glioma risk in different ethnic groups. Ann Epidemiol 25:270-4
|
|
Sayour, Elias J; McLendon, Pat; McLendon, Roger et al. (2015) Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother 64:419-27
|
Showing the most recent 10 out of 178 publications
